Eksigent Moves NanoLC Distribution into France with Serlabo Technologies
News Mar 06, 2007
Eksigent, a developer of advanced low-flow fluid delivery technologies for drug discovery and other life science applications, has announced a new distribution agreement with France-based Serlabo Technologies.
The exclusive agreement covers sales and service of Eksigent’s NanoLC™ HPLC product line in France.
Serlabo Technologies specializes in sales, application support and maintenance of chromatography, spectroscopy and other biotech instruments. With a staff of 27, the company offers a line of chromatography solutions.
“We’re pleased to continue our European expansion with this latest distribution agreement,” commented David Weber, Eksigent’s President and CEO. “We have carefully selected Serlabo based on their relationships with commercial and academic scientists and opinion leaders. The addition of our products to their portfolio clearly helps them better serve their customers’ needs.”
“The Eksigent NanoLC systems are an excellent offering for proteomics applications,” commented Gerard Zambon, Sales Director for Serlabo. “Eksigent will be a key partner in the expansion of our installed base.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.